National Comprehensive Cancer Network (NCCN) category I/FDA-approved metastatic pancreatic adenocarcinoma (mPDAC) treatments in commercially insured patients: An analysis of inpatient (IP) and emergency room (ER) admissions.

Paul Cockrum,Andy Surinach,Stella Arndorfer,Jim M. Koeller,George P. Kim

National Comprehensive Cancer Network (NCCN) category I/FDA-approved metastatic pancreatic adenocarcinoma (mPDAC) treatments in commercially insured patients: An analysis of inpatient (IP) and emergency room (ER) admissions.

2020

Paul Cockrum
Andy Surinach
Stella Arndorfer
Jim M. Koeller
George P. Kim

e16739Background: There are currently four NCCN category 1 systemic regimens approved in the United States for the treatment of mPDAC: FOLFIRINOX (FFX), gemcitabine+nab-paclitaxel (gem+nab-P), gemc...

Keywords:

Cancer
Oncology
Internal medicine
Pathology
Metastatic Pancreatic Adenocarcinoma
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations